Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Endocrine 8NET 3Sarcoma 2Gastrointestinal 2Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Colorectal Neoplasms 3979Pancreatic Neoplasms 2480Carcinoma, Hepatocellular 2416Stomach Neoplasms 2109Rectal Neoplasms 1676Colonic Neoplasms 1629Esophageal Neoplasms 1312Liver Neoplasms 879Neoplasms 635Breast Neoplasms 596Cholangiocarcinoma 529Gastrointestinal Neoplasms 468Neoplasm Metastasis 456Esophageal Squamous Cell Carcinoma 434Lung Neoplasms 422Biliary Tract Neoplasms 277Prostatic Neoplasms 271Ovarian Neoplasms 237Barrett Esophagus 224Adenocarcinoma Of Esophagus 202Gallbladder Neoplasms 194Head and Neck Neoplasms 186Carcinoma, Non-Small-Cell Lung 185Gastrointestinal Stromal Tumors 180Anus Neoplasms 179Recurrence 168Melanoma 163Adenocarcinoma 156Uterine Cervical Neoplasms 154Bile Duct Neoplasms 153

Interventions

pasireotide 1Diazoxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Hypoglycemia × Gastrointestinal × Clear all
NCT06041906 2025-06-18

IRCPSS

University Hospital, Geneva

Enrolling by invitation
500 enrolled
Gastrointestinal

Congenital Portosystemic Shunt, Hepatic Encephalopathy, Hyperinsulinism, Hypertension, Pulmonary, Hypoglycemia, Insulin Resistance, Liver Neoplasms, Hyperandrogenism, Hepatopulmonary Syndrome, Hyperammonemia, Rare Diseases, Vascular Malformations

NCT02779257 2022-03-04

Pasireotide Treatment for Neuroendocrine Tumor

University of Maryland, Baltimore

Phase 4 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Hypoglycemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡